Immutep Ltd (IMM) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.233x

Based on the latest financial reports, Immutep Ltd (IMM) has a cash flow conversion efficiency ratio of -0.233x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-33.50 Million ≈ $-23.71 Million USD) by net assets (AU$143.64 Million ≈ $101.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IMM market cap for the company's overall valuation and market capitalisation.

Immutep Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Immutep Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Immutep Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Immutep Ltd ranked by their cash flow conversion efficiency. See Immutep Ltd debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.

Company Cash Flow Conversion Efficiency
LTKM Bhd
KLSE:7085
0.004x
Koan Hao Technology Co Ltd
TWO:8354
0.003x
Space Com
TA:SCC
-0.893x
Lake Victoria Gold Ltd.
V:LVG
-0.070x
Diginex Limited Ordinary Shares
NASDAQ:DGNX
-0.503x
ALANDEQGRP FPO
AU:AEG
-1.327x
Componenta Corp
HE:CTH1V
0.115x
JP Morgan Global Growth & Income PLC
LSE:JGGI
0.004x

Annual Cash Flow Conversion Efficiency for Immutep Ltd (2004–2025)

The table below shows the annual cash flow conversion efficiency of Immutep Ltd from 2004 to 2025. View IMM share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$143.64 Million
≈ $101.63 Million
AU$-62.05 Million
≈ $-43.90 Million
-0.432x -135.12%
2024-06-30 AU$189.52 Million
≈ $134.10 Million
AU$-34.82 Million
≈ $-24.64 Million
-0.184x +30.12%
2023-06-30 AU$136.47 Million
≈ $96.56 Million
AU$-35.88 Million
≈ $-25.39 Million
-0.263x +18.17%
2022-06-30 AU$94.08 Million
≈ $66.57 Million
AU$-30.23 Million
≈ $-21.39 Million
-0.321x -33.47%
2021-06-30 AU$73.27 Million
≈ $51.84 Million
AU$-17.64 Million
≈ $-12.48 Million
-0.241x +26.04%
2020-06-30 AU$33.30 Million
≈ $23.56 Million
AU$-10.84 Million
≈ $-7.67 Million
-0.326x +48.07%
2019-06-30 AU$24.39 Million
≈ $17.26 Million
AU$-15.29 Million
≈ $-10.82 Million
-0.627x -176573.57%
2018-06-30 AU$33.52 Million
≈ $23.72 Million
AU$-11.89K
≈ $-8.42K
0.000x +99.89%
2017-06-30 AU$26.53 Million
≈ $18.77 Million
AU$-8.51 Million
≈ $-6.02 Million
-0.321x -0.12%
2016-06-30 AU$35.32 Million
≈ $24.99 Million
AU$-11.31 Million
≈ $-8.00 Million
-0.320x -1.53%
2015-06-30 AU$24.69 Million
≈ $17.47 Million
AU$-7.79 Million
≈ $-5.51 Million
-0.315x +49.92%
2014-06-30 AU$22.59 Million
≈ $15.99 Million
AU$-14.23 Million
≈ $-10.07 Million
-0.630x -14.85%
2013-06-30 AU$29.25 Million
≈ $20.70 Million
AU$-16.04 Million
≈ $-11.35 Million
-0.548x -6.56%
2012-06-30 AU$37.16 Million
≈ $26.29 Million
AU$-19.12 Million
≈ $-13.53 Million
-0.515x -190.62%
2011-06-30 AU$55.10 Million
≈ $38.99 Million
AU$-9.76 Million
≈ $-6.90 Million
-0.177x +54.00%
2010-06-30 AU$16.79 Million
≈ $11.88 Million
AU$-6.46 Million
≈ $-4.57 Million
-0.385x +62.96%
2009-06-30 AU$1.81 Million
≈ $1.28 Million
AU$-1.88 Million
≈ $-1.33 Million
-1.039x -76.06%
2008-06-30 AU$2.63 Million
≈ $1.86 Million
AU$-1.55 Million
≈ $-1.10 Million
-0.590x +27.67%
2007-06-30 AU$4.08 Million
≈ $2.89 Million
AU$-3.33 Million
≈ $-2.36 Million
-0.816x -2.03%
2006-06-30 AU$6.32 Million
≈ $4.47 Million
AU$-5.05 Million
≈ $-3.57 Million
-0.800x -40.92%
2005-06-30 AU$8.34 Million
≈ $5.90 Million
AU$-4.73 Million
≈ $-3.35 Million
-0.568x +48.43%
2004-06-30 AU$5.13 Million
≈ $3.63 Million
AU$-5.64 Million
≈ $-3.99 Million
-1.100x --

About Immutep Ltd

AU:IMM Australia Biotechnology
Market Cap
$41.66 Million
AU$58.88 Million AUD
Market Cap Rank
#22677 Global
#820 in Australia
Share Price
AU$0.04
Change (1 day)
+5.26%
52-Week Range
AU$0.04 - AU$0.46
All Time High
AU$0.68
About

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more